Journal article
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
WP Tan, A Plata Bello, C Garcia Alvarez, F Guerrero-Ramos, DA González-Padilla, C Nzeh, J Manuel De La Morena, IGV De Torres, K Hendricksen, FJ Díaz Goizueta, JF Del Álamo, F Chiancone, P Fedelini, M Poggio, F Porpiglia, VC Gonzalo Rodríguez, JM Torres, D Wilby, R Robinson, A Sousa-Escandón Show all
Bladder Cancer | Published : 2022
DOI: 10.3233/BLC-220026
Abstract
INTRODUCTION: High grade, non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical Bacillus Calmette-Guérin. Chemohyperthermia therapy (CHT) may be a novel alternative therapy for the treatment of NMIBC. OBJECTIVE: To evaluate the recurrence-free survival (RFS) of patients treated with CHT using the Combat bladder recirculation system (BRS) for NMIBC. METHODS: This was a prospective multi-institutional study of 1,028 consecutive patients with NMIBC undergoing CHT between 2012 and 2020. A total of 835 patients were treated with CHT with Mitomycin C (MMC). Disease was confirmed on transurethral resection of bladder tumor (TURBT) prior to starting CHT. Follow-up included ..
View full abstractGrants
Awarded by National Health and Medical Research Council